Preclinical evaluation of two potential agents for these targets emphasized the higher efficacy of anti-CD52 therapy as consolidation after prior ibrutinib treatment, potentially minimizing survival of residual, resistant cells and improving prognosis of MCL patients. The gene discussed is CD52; the disease is mantle cell lymphoma.